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A number of new biological markers are being studied as
predictors of disease or adverse medical events among
those who already have a disease. Systematic reviews of
this growing literature can help determine whether the
available evidence supports use of a new biomarker as a
prognostic test that can more accurately place patients
into different prognostic groups to improve treatment
decisions and the accuracy of outcome predictions.
Exemplary reviews of prognostic tests are not widely
available, and the methods used to review diagnostic
tests do not necessarily address the most important
questions about prognostic tests that are used to predict
the time-dependent likelihood of future patient out-
comes. We provide suggestions for those interested in
conducting systematic reviews of a prognostic test. The
proposed use of the prognostic test should serve as the
framework for a systematic review and to help define the
key questions. The outcome probabilities or level of risk
and other characteristics of prognostic groups are the
most salient statistics for review and perhaps meta-
analysis. Reclassification tables can help determine how
a prognostic test affects the classification of patients into
different prognostic groups, hence their treatment. Re-
view of studies of the association between a potential
prognostic test and patient outcomes would have little
impact other than to determine whether further devel-
opment as a prognostic test might be warranted.
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INTRODUCTION
With increasing frequency, multiple objective measures of
normal or pathologic biological processes as well as measures
of social, psychological, behavioral and demographic features
are being associated with important patient outcomes. Some of
these measures, singly or in combination as a prediction
model, can be clinically useful. The plethora of potential new
prognostic tests and prediction models, like treatments and
diagnostic tests, is an appropriate topic for systematic review.
Such reviews can serve to summarize available evidence, as
well as guide further research regarding the usefulness of the
test. The questions that are most salient for clinical practice,
and hence a systematic review concern the accuracy of
predictions derived from a test or prediction model, and how
the results affect patient management and outcomes.
This paper is meant to complement the Evidence-based
Practice Center Methods Guide for Comparative Effectiveness
Reviews, and is not a comprehensive or detailed review of
methods that could be used to conduct a systematic review of
a prognostic test. Generally speaking, the steps for reviewing
evidence for prognostic tests are similar to those used in the
review of a diagnostic test and discussed in other papers in
this Medical Test Methods Guide. These steps include: 1)
using the population, intervention, comparator, outcomes,
timing and setting (PICOTS) typology and an analytic
framework to develop the topic and focus the review on the
most important key questions, 2) conducting a thorough
literature search, 3) assessing the quality of reported studies,
4) extracting and summarizing various types of statistics from
clinical trials and observational studies, and 5) meta-analyzing
study results. However, important differences between diag-
nostic and prognostic tests highlighted here should be
considered when planning and conducting a review.
Step 1: Developing the Review Topic and Framework
Developing the review topic, including the
framework for thinking about the relationship
between the test and patient outcomes, as well as
the key questions, can be fundamentally different for
diagnostic and prognostic tests. A diagnostic test is
used to help determine whether a patient has a
disease at the time the test is performed. Evaluations
of diagnostic tests often use a categorical reference
test (gold standard) to determine the true presence or
absence of the disease. Typically patients are
classified as diagnostic test positive or negative to
estimate the test’s accuracy as sensitivity (true
positive fraction) and specificity (true negative
fraction). In contrast, a prognostic test is used to
predict a patient’s likelihood of developing a disease
or experiencing a medical event. Therefore, the
“reference test” for a prognostic test is the observed
proportion that develop what is being predicted.
For practical purposes, it is often useful to
group the results of a prognostic test into
parsimonious categories corresponding to the
implications for decision making. For example, if
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no further evaluation or treatment of “low” risk
cases, initiation of treatment or prevention in
“high” risk cases, or further tests or monitoring
for “intermediate” risk cases, then it would be
useful to structure the review according to these
prognostic test categories (low, intermediate and
high risk) and clearly define each group including
its outcome probabilities. If a decision model is
used as the framework for a systematic review and
meta-analysis of a prognostic test, the precision
and accuracy of estimates of outcome probabilities
within these different prognostic groups may be
the primary focus. These considerations, among
others are summarized in Table 1, which provides
a general PICOTS framework for systematically
reviewing prognostic tests.
In some contexts, it may be informative to
categorize subjects as those who did or did not
experience the predicted outcome within a spec-
fied time interval and then look back to categorize
the results of the prognostic test. Much as for a
diagnostic test, a systematic review of a prognostic
test could then assess the accuracy of the
prognostic test by calculating the sensitivity and
specificity and predictive values for that point in
time. An essential factor to consider in a review is
what follow-up times are especially informative to
patients, clinicians or policymakers.
A somewhat unique category of prognostic tests
are those that can be used to predict beneficial or
adverse responses to a treatment commonly known
as predictive tests. Evidence about the value of a
predictive test typically is presented as separate
estimates of the treatment effect in subgroups
defined by the predictive test along with a statistical
test for interaction. Systematic reviews of predictive
test/treatment interactions are not specifically dis-
cussed in this paper. Interested readers are referred
to publications on this topic
1
Step 2: Searching for Studies
When developing the literature search strategy,
it is important to recognize that studies can relate
to one or more of the following categories
2.
1. Proof of concept: Is the test result associated with a
clinically important outcome?
2. Prospective clinical validation: How accurately does the
test predict outcomes in different cohorts of patients,
clinical practices and prognostic groups?
3. Incremental predictive value: How much does the new
prognostic test change predicted probabilities and
increase the discrimination of patients who did or did
not experience the outcome of interest within a specific
time period?
4. Clinical utility: Does the new prognostic assessment
change predicted probabilities enough to reclassify
many patients into different prognostic groups that
would be managed differently?
5. Clinical outcomes: Would use of the prognostic test
improve patient outcomes?
6. Cost effectiveness: Do the improvements in patient
outcomes justify the additional costs of testing and
subsequent medical care?
Each phase of development is focused on different
types of questions, research designs, and statistical
methods although a single study might address several
of these questions. Large cohort studies and secondary
analyses of clinical trials may be the most readily
available evidence to answer the first four types of
questions. For the latter two types of questions,
randomized controlled trials of prognostic tests are
preferred. However, they can be costly and time
consuming, and thus are rarely done by stakeholders
3.
Before embarking on a review focused on the last two
types of key questions, reviewers need to think about
what they would do, if anything, in the absence of
randomized controlled studies of the effect of a
prognostic test on patient outcomes. One option is to
use a decision model to frame the review and focus on
providing the best estimates of outcome probabilities.
Reliable and validated methods to exhaustively search
the literature for information about prognostic tests have
not been established, and the best bibliographic indexes
and search strategies have yet to be determined. Some
search strategies have been based on variations of key
Table 1. General PICOTS Typology for Review of Prognostic Tests
Population Clinical spectrum and other characteristics of the
prognostic groups including the observed probabilities
of the outcome being predicted
Intervention The prognostic test or assessment including all
components, exactly what it measures, how it is done,
how clinical specimens are obtained, processed, and
stored for testing, exactly what is being predicted and
how the test results are to be interpreted and used by
test operators
Comparator Standard prognostic tests or assessments for predicting
the same outcome
Outcomes Time-dependent probabilities (time-to-event curves) of
what is being predicted, changes or differences in
predicted outcome probabilities or reclassification of
patients into different prognostic groups, changes in
patient care, the net effect of using the prognostic test
on patient outcomes, and cost effectiveness
Timing At what stage in the natural history of outcome
development is the prognostic test to be used? How
much follow-up time does the prognostic test cover?
The percentage of patients who experience the
outcome usually increases with time thereby changing
the performance charactersitics of prognostic tests
Setting Who will use prognostic test? How? What is the
applicable testing scenario?
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publications meeting the study selection crtieria
4.O t h e r s
have used search terms such as “cohort,”“ incidence,”
“mortality,”“ follow-up studies,”“ course,” or the word
roots “prognos-” and “predict-” to identify relevant
studies
5. Obviously, the range of terms used to describe
the prognostic test(s) and the clinical condition or medical
event to be predicted should be used as well. The “find
similar” or “related article” functions available in some
indexes may be helpful. A manual search of reference lists
will need to be done. If a prognostic test has been
submitted for review by regulatory agencies such as the
Food and Drug Administration, the records that are
available for public review should be searched. The
website of the test producer could provide useful
information too.
In contrast to diagnostic tests, many prognostic tests
are incorporated into multivariable regression models or
algorithms for prediction. Many reports in the literature
only provide support for an independent association of
a particular variable with the patient outcome that might
be useful as a prognostic test
6,7. The converse—that a
test variable did not add significantly to a multivariable
regression model—is difficult to find, particularly via
an electronic search or abstract reviews when the focus
is often on positive findings
8. Given the potential bias
introduced by failing to uncover evidence of lack of a
strong association, hence predictive value, if a review is
going to focus on proof-of-concept questions, all
studies that included the test variable should be sought
out, reviewed, and discussed even when the study
merely mentions that the outcome was not indepen-
dently related to the potential prognostic test or a
component of a multivariable prediction model
9.
Whenever a systematic review focuses on key ques-
tions about prognostic groups that are defined by
predicted outcome probabilities, reviewers should search
for decision analyses, guidelines, or expert opinions that
help support the outcome probability thresholds used to
define clinically meaningful prognostic groups, that is,
groups that would be treated differently in practice
because of their predicted outcome. Ideally, randomized
controlled clinical trials of medical interventions in
patients selected based on the prognostic test would help
establish the rationale for using the prognostic test to
classify patients into the prognostic groups (although this
is not always sufficient to evaluate this use of a
prognostic test)
1,3.
Step 3: Selecting Studies and Assessing Quality
Previous reviews of prognostic indicators have
demonstrated substantial variation in study design,
subject inclusion criteria, methods of measuring
key variables, follow-up time, methods of analysis
(including definition of prognostic groups), adjust-
ments for covariates, and presentation of results
10–12.
Some of these difficulties could be overcome if
reviewers were given access to the individual
patient-level data from studies, which would allow
them to conduct their own analyses in a more
uniform manner. Lacking such data, several sugges-
tions have been made for assessing studies to make
judgments about the quality of reports and whether
to include or exclude them from a review
5,13,14.
Table 2 lists questions that should be considered. At
this time, reviewers will need to decide which of
these general criteria or others are appropriate for
judging studies for their particular review. As
always, reviewers should be explicit about any
criteria that were used to exclude or include studies
from a review. Validated methods to use criteria to
score the quality of studies of prognostic tests need
to be developed.
Comparisons of prognostic tests should use
data from the same cohort of subjects to minimize
confounding the comparison. Within a study, the
prognostic tests being compared should be con-
ducted at the same time to ensure a common
starting point with respect to the patient outcome
Table 2. Outline of Questions for Judging the Quality of
Individual Studies of Prognostic Tests
1. Was the study designed to evaluate the new prognostic test, or was it
a secondary analysis of data collected for other purposes?
2. Were the subjects somehow referred or selected for testing? What
was the testing scenario?
3. Was the clinical population clearly described including the sampling
plan, inclusion and exclusion criteria, subject participation, and the
spectrum of test results? Did the sample represent patients that
would be tested in clinical practice?
4. Did everyone in the samples have a common starting point for
follow-up with respect to the outcome of interest including any
treatments that could affect the outcome being predicted?
5. Were the prognostic tests clearly described and conducted using a
standardized, reliable, and valid method?
a. Was the test used and interpreted the same way by all sites/studies
including any interdeterminate test results?
b. Were the test results ascertained without knowledge of the outcome?
c. Were investigators blinded to the test results?
d. How were previously established prognostic indicators or other
prognostic assessments included in the study and analyses?
6. Was the outcome being predicted clearly defined and ascertained
using a standardized, reliable, and valid method?
a. How complete was the follow-up of subjects, and were losses to
follow-up related to the test results or the outcome being predicted?
b. Was the duration of follow-up adequate?
7. Were the data used to develop the prognostic test?
a. Were the prognostic groups pre-defined based on clinically
meaningful decision thresholds for predicted outcome probabilities?
b. Were the results externally validated using an independent sample
or internally validated via boot strap or cross-validation methods?
c. Were any previously established prognostic indicators or prediction
models being used as comparators fit to the sample data in the same
manner as the potential new prognostic test?
d. Were outcome predictions adjusted for any other factors? Which
ones? How?
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starting point of each study reviewed. All of the
prognostic test results and interpretation should be
ascertained without knowledge of the outcome to
avoid ascertainment bias. Investigators should be
blinded to the results of the prognostic test to
avoid selective changes in treatment that could
affect the outcome being predicted. Reviewers
need to be aware of any previously established
prognostic indicators that should be included in a
comparative analysis of potential new prognostic
tests, and pay close attention to that with which a
new prognostic test is compared. Any adjustments
for covariates that could make studies more or less
comparable also need to be noted
15.
If the investigators fit a new prognostic test or
prediction equation to the sample data (test
development sample) by using the data to define
cut-off levels or model its relationships to the
outcome and estimate regression coefficient(s), the
estimated predictive performance can be overly
optimistic. In addition, the fitting might bias the
comparison to an established prognostic method
that was not fit to the same sample.
Step 4: Extracting Statistics to Evaluate Test Performance
The summary statistics reported in the selected
articles need to be appropriate for the key question
(s) the review is trying to address. For example,
investigators commonly report estimated hazard
ratios from Cox regression analyses or odds ratios
from logistic regression analyses to test for
associations between a potential prognostic test
and the patient outcome. These measures of
association address only early phases in the
development of a potential prognostic test—proof
of concept and perhaps validation of a potentially
predictive relationship to an outcome in different
patient cohorts, and to a very limited extent the
potential to provide incremental predictive value.
Potential predictors that exhibit statistically signif-
icant associations with an outcome often do not
substantially discriminate between subjects who
eventually do or do not experience the outcome
event because the distributions of the test result in
the two outcome groups often overlap substantial-
ly even when the means are highly significantly
different
16,17. Statistically significant associations
(hazard ratios, relative risk, or odds ratios) merely
indicate that more definitive evaluation of a new
predictor is warranted
18,19. Nevertheless, for
reviewers who are interested in these associations,
there are well-established methods for summariz-
ing estimates of hazard, relative risks or odds
ratios
20–23. However, the questions a systematic
review could answer about the use of a prognostic
test by summarizing its association with an
outcome are quite limited and not likely to impact
practice. More relevant are the estimates of
absolute risk in different groups.
Discrimination statistics. The predictive perfor-
mance of prognostic tests is often reported in a
manner similar to diagnostic tests using estimates
of sensitivity, specificity, and the area under the
receiver operating characteristic (ROC) curve at
one particular follow-up time. These indices of
discrimination can be calculated retrospectively and
compared when a new prognostic indicator is
added to a predictive model or a prognostic test is
compared to predictions made by other methods,
including experienced clinicians
24–27. However,
these backward-looking measures of discrimination
do not summarize the predicted outcome probabil-
ities and do not directly address questions about the
predictions based on a new prognostic test or its
impact on patient outcomes
28–30. The next section
on reclassification tables describes other measures
of test discrimination that can help reviewers
assess, in part, the clinical impact of prognostic
tests. If reviewers elect to use the more familiar and
often reported discrimination statistics, then they
must be cognizant of the fact that they change over
time as more patients develop the outcome being
predicted. Time-dependent measures of sensitivity,
specificity, and the ROC curve have been devel-
oped
31.H a r r e l l ’s C-statistic is conceptually similar
to an area under an ROC curve and can be derived
from time-to-event analyses
32,33. Examples of
systematic reviews and meta-analyses of prognostic
tests that used these time-dependent measures of
discrimination were not found.
Reclassification tables. The clinical usefulness of
a prognostic test depends largely on its ability to
place patients into different prognostic groups and
provide accurate predictions about their future
health. For example, expert guidelines use prog-
nostic groups defined by the estimated 10-year
risk of developing cardiovascular disease (<10%,
10 to 20% and >20%) based on the Framingham
cardiovascular risk score to help determine wheth-
er to recommend interventions to prevent future
cardiovascular events
34. Analyses of reclassifica-
tion tables are now being reported to determine
how adding a prognostic test reclassifies patients
into the prognostic groups
35–38. Table 3 shows a
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Ideally, the classification of outcome probabilities
into prognostic groups (arbitrarily set at an
individual predicted probability >0.10 in the
example) should be based on outcome probabili-
ties that will lead to different courses of action. If
not, the reviewer needs to take note, because the
observed reclassifications could be clinically
meaningless in the sense that they might not be
of sufficient magnitude to alter the course of
action; that is to say, some reclassification of
patients by a prognostic test might not make any
difference in patient care. In the example, adding
the new prognostic test reclassified 10% of the
1000 people originally in the lower risk group and
25% of the 400 people in the higher risk group.
Reclassification tables typically provide informa-
tion about the observed outcome probabilities in
each prognostic group (summarized as percentages
in the example) and the predicted probabilities.
However, this information is often limited to a
single follow-up time, and the precision of the
estimates might not be reported. The differences
between the estimated probabilities and observed
outcomes for each prognostic group might be
analyzed by a chi-square goodness-of-fit test
39.
However, these results will not help the reviewer
determine if the differences in predicted and
observed probabilities are substantially better when
the new prognostic test is added. In the example
depicted in Table 3, the differences between
predicted and observed values for each prognostic
test shown in the column and row totals are small,
as expected whenever prognostic groups have a
narrow range of individual predicted probabilities
and the prediction models are fit to the data rather
than applied to a new sample.
Reviewers might also encounter articles that
report separate reclassification tables for patients
who did or did not experience the outcome event
within a specific period of time along with a
summary statistic known as the net reclassification
improvement (NRI)
40. In the group that developed
the outcome event within the specified period of
time, the net improvement is the proportion of
patients who were reclassified by a prognostic test
into a higher probability subgroup minus the
proportion who were reclassified into a lower
probability subgroup. In a 2-by-2 reclassification
table of only subjects who experienced the outcome
event (e.g., those who died), this net difference is
the estimated change in test sensitivity. In the group
who did not experience the outcome event, the net
improvement is the proportion of patients who were
reclassified into a lower probability subgroup
minus the proportion who were reclassified into a
higher probability subgroup. In a 2-by-2 reclassifi-
cation table of only subjects who did not experi-
ence the event within the follow-up period (e.g.,
those who survived), this net difference is the
estimated change in specificity. The NRI is the
simple sum of net improvement in classifcation of
patients that did or did not experience the outcome.
If these calculations use the mean changes in
individual predicted probabilities in the patients that
did or did not experience the outcome, the result is
known as the integrated discrimination index (IDI).
Another formulation of the NRI calculates the
probabilities of the predicted event among those
that have an increase in their predicted probability
given the results of a new prognostic test, the
probabilities of the predicted event among those that
have a decrease in their predicted probability, and
the event probability in the overall sample
41.T h e s e
three probabilities can be estimated by time-to-event
analysis but still only represent a single point of
follow-up. This so-called continuous formulation of
the NRI doesn’t require one to define clinically
meaningful prognostic categories. Rather, it focuses
on subjects that have, to any degree, a higher or
lower predicted outcome probability when a new
prognostic test is employed. Not all increases or
decreases in predicted probabilities would be
clinically meaningful in the sense that they would
prompt a change in patient management.
Table 3. Example Reclassification Table Based on Predicted
Outcome Probabilities
Grouped mortality
probabilities estimated by
the first prognostic test
Grouped mortality probabilities
estimated by the first prognostic
test + a new prognostic test
0 to 0.10 > 0.10 Total
0 to 0.10
Patients in prognostic group 900 100 (10%) 1000
Mortality predictions using
1
st test
4.0% 8.0% 4.40%
Mortality prediction using
both tests
3.8% 11.0% -
Observed mortality 3.9% 12.0% 4.7%
> 0.10
Patients in prognostic group 100 (25%) 300 400
Mortality predictions using
1
st test
15.0% 17.0% 16.5%
Mortality prediction using
both tests
9.0% 19.0% -
Observed mortality 10.0% 19.0% 16.8%
Total
Patients in prognostic group 1000 400 1400
Mortality prediction using
both tests
4.3% 17.0% -
Observed mortality 4.5% 17.2% 8.2%
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studies could be gleaned from the literature
comparing prognostic tests. Several issues need
to be examined before trying to pool estimates
from different studies. Reviewers should make
sure the characteristics of prognostic groups,
definition of the outcome event, overall probabil-
ity of the event and the follow-up time did not
vary substantially between studies.
Predictive values. Treatment decisions based on
outcome probabilities are often dichotomous—for
example, “treat those at high-risk” and “don’tt r e a t
those at low-risk” groups. If patients would be
treated because a prognostic test indicates they are
“high risk”, then the observed time-dependent
percentages of patients developing the outcome
without treatment are essentially positive predictive
values(i.e. the proportion of those with a ‘positive’
prognostic test that have the event). If clinicians
would not treat patients in the lower risk group,
then one minus the observed time-dependent
outcome probabilities are the negative predictive
values (i.e. the proportion of those with a ‘negative’
prognostic test that don’t have the event). For a
single point of follow-up, these positive and
negative predictive values can be compared using
methods devised for comparing predictive values of
diagnostic tests. Most likely the ratios of positive
and negative predictive values of two prognostic
tests will be summarized in a report, along with a
confidence interval
42. The regression model pro-
posed by Leisenring and colleagues might be used
to determine how patient characteristics relate to the
relative predictive values
43. Methods to compare
predictive values of two prognostics tests that are in
the form of time-to-event curves are available if
encountered during a review
44–47.
Step 5: Meta-Analysis ofEstimatesofOutcomeProbabilities
The most definitive level of evidence to answer
the most important questions about a prognostic
test or comparison of prognostic tests would come
from randomized controlled trials designed to
demonstrate a net improvement in patient out-
comes and cost-effectiveness. Many studies of
prognostic tests do not provide this ultimate
evidence. However, a systematic review could
provide estimates of outcome probabilities for
decision models
48. Estimates could come from
either randomized controlled trials or observation-
al studies as long as the prognostic groups they
represent are well-characterized and similar. A
meta-analysis could provide more precise esti-
mates of outcome probabilities. In addition, meta-
analysis of estimated outcome probabilities in a
prognostic group extracted from several studies
may provide some insights into the stability of the
estimates and whether variation in the estimates is
related to characteristics of the prognostic groups.
Methods have been developed to combine
estimates of outcome probabilities from different
studies
20. Dear’s method uses a fixed effects
regression model while Arend’s method is similar
to a DerSimonian–Laird random-effects model
when there is only one common follow-up time
for all studies/prognostic groups in the analy-
sis
49,50. These references should be consulted if
interested in this type of meta-analysis.
CONCLUSION
There’s a large and rapidly growing amount of literature
about prognostic tests. A systematic review can determine
what is known and what needs to be determined to support
use of a prognostic test by decision makers. Hopefully, this
guidance will be helpful to reviewers who want to conduct
an informative review of a prognostic test, and spur efforts
to establish consensus methods for reporting studies of
prognostic tests and conducting reviews of them.
KEY POINTS
& Methods to conduct a clinically oriented systematic
review of a prognostic test are not well established.
Several issues discussed herein will need to be
addressed when planning and conducting a review.
& The intended use of the prognostic test under review
needs to be specified, and predicted probabilities need to
be classified into clinically meaningful prognostic
groups, i.e. those that would be treated differently. The
resultant prognostic groups need to be described in
detail including their outcome probabilities.
& A large number of published reports focus on the
associations between prognostic indicators and patient
outcomes, the first stage of development of prognostic
tests. A review of these types of studies would have
limited clinical value.
& Criteria to evaluate and score the quality of studies of
prognostic tests have not been firmly established.
Reviewers can adapt criteria that have been developed
for judging studies of diagnostic tests and cohort studies
with some modifications for differences inherent in studies
of prognostic tests. Suggestions are listed in Table 2.
& Given the fundamental difference between diagnostic
tests that determine the current health state of disease
S99 Rector et al.: Systematic Review of Prognostic Tests JGIMand prognostic tests that predict a future state of disease,
some of the most commonly used statisitcs for evaluat-
ing diagnostic tests, such as point estimates of test
sensitivity and specificity and receiver operator charac-
teristic curves, are not as informative for prognostic
tests. The most pertinent summary statistics for prog-
nostic tests are the time-dependent observed outcome
probabilities within clearly defined prognostic groups,
the closeness of each group’s predicted probabilities to
the observed outcomes, and how use of a new
prognostic test reclassifies patients into different prog-
nostic groups and improves predictive accuracy and
overall patient outcomes.
& Methods to compare and summarize the predictive
performance of prognostic tests need further development
and widespread use to facilitate systematic reviews.
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